Edoxaban (LIXIANA®) in the treatment of venous thromboembolism.

Abstract

Standard therapy for venous thromboembolism (VTE) includes the use of heparins and vitamin K antagonists. Randomized clinical trials have shown that non-vitamin K oral anticoagulants are as effective and safe as standard therapy in VTE treatment, with an improved pharmacological profile. Edoxaban, a direct inhibitor of factor Xa, has demonstrated noninferiority to standard therapy for the treatment of VTE, preserving a high safety profile even in long-term therapy, in frail patients and in severe clinical presentations. The present paper focuses on the role of edoxaban in VTE treatment, from general population to cancer patients, presenting the available data from randomized clinical trials and real world, to discuss edoxaban use in clinical practice.

• Authors: Roberta Bottino, Andreina Carbone, Biagio Liccardo, Antonello D'Andrea, Anna Rago, Andrea Antonio Papa, Carmen Spaccarotella, Paolo Golino, Gerardo Nigro, Vincenzo Russo
• Journal: Future cardiology (Future Cardiol) Vol. 17 Issue 5 Pg. 779-791 (08 2021) ISSN: 1744-8298 [Electronic] England
• PMID: 33231106 (Publication Type: Journal Article)

Chemical References

• Factor Xa Inhibitors
• Pyridines
• Thiazoles
• edoxaban

Topics

• Factor Xa Inhibitors (therapeutic use)
• Humans
• Pyridines (therapeutic use)
• Thiazoles (therapeutic use)
• Venous Thromboembolism (drug therapy)